A Dual Inhibitor Treatment for RA?

TLL-018, a Janus kinase 1/tyrosine kinase 2 inhibitor, proved more effective for treating patients with RA than tofacitinib, according to a study by Zeng et al.

Source: The Rheumatologist - July 17, 2023 Category: Rheumatology Authors: Michele B. Kaufman, PharmD, BCGP Tags: DMARDs & Immunosuppressives Drug Updates Meeting Reports Source Type: research